HRP20240794T1 - Analozi rapamicina i njihove uporabe - Google Patents
Analozi rapamicina i njihove uporabe Download PDFInfo
- Publication number
- HRP20240794T1 HRP20240794T1 HRP20240794TT HRP20240794T HRP20240794T1 HR P20240794 T1 HRP20240794 T1 HR P20240794T1 HR P20240794T T HRP20240794T T HR P20240794TT HR P20240794 T HRP20240794 T HR P20240794T HR P20240794 T1 HRP20240794 T1 HR P20240794T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- compound
- pharmaceutically acceptable
- disease
- compound according
- Prior art date
Links
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims 1
- 208000002814 Autosomal Recessive Polycystic Kidney Diseases 0.000 claims 1
- 208000017354 Autosomal recessive polycystic kidney disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000037416 cystogenesis Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000026585 laminopathy Diseases 0.000 claims 1
- 201000009925 nephrosclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims 1
- 230000009758 senescence Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
Claims (6)
1. Spoj, naznačen time, da je predstavljen Formulom II:
[image]
ili njegova farmaceutski prihvatljiva sol;
gdje se R1 bira od sljedećih:
[image]
[image]
2. Spoj prema patentnom zahtjevu 1, naznačen time, da se spoj bira između bilo koje od Formula II-a i II-b:
[image]
ili njegova farmaceutski prihvatljiva sol.
3. Spoj prema patentnom zahtjevu 1, naznačen time, da se spoj bira od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
4. Farmaceutski prihvatljiv pripravak, naznačen time, da sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 3, i farmaceutski prihvatljiv nosač, pomoćno sredstvo, ili prijenosno sredstvo.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, ili njegov farmaceutski pripravak, naznačen time, da je za uporabu u postupku za liječenje mTORC-posredovane bolesti, poremećaja, ili stanja kod pacijenta kojemu je to potrebno, dok postupak obuhvaća davanje spomenutom pacijentu navedeni spoj; opcionalno, gdje se mTORC-posredovana bolest, poremećaj, ili stanje bira od sljedećih: dijabetička nefropatija, komplikacije dijabetesa tipa 1 i dijabetesa tipa 2, koje se odnose na bubrege, autosomno dominantna policistična bubrežna bolest (ADPBB), autosomno recesivna policistična bubrežna bolest (ARPBB), bolesti bubrega povezane sa cističnim formacijama ili cistogenezom, fokalna segmentalna glomeruloskleroza (FSGS) i ostale bolesti povezane sa sklerozom bubrega, laminopatije, makularna degeneracija povezana sa starenjem (AMD), dijabetički makularni edem, dijabetička retinopatija, glaukom, retinalna bolest povezana sa starenjem, senescencija imunosnog sustava, infekcije respiratornog trakta, infekcije urinarnog trakta, zastoj srca, osteoartritis, plućna arterijska hipertenzija (PAH), i kronična opstruktivna plućna bolest (KOPB).
6. Spoj za uporabu prema patentnom zahtjevu 5, naznačen time, da postupak nadalje obuhvaća davanje dodatnog terapijskog sredstva u kombinaciji s navedenim spojem.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685666P | 2018-06-15 | 2018-06-15 | |
| PCT/US2019/037507 WO2019241789A1 (en) | 2018-06-15 | 2019-06-17 | Rapamycin analogs and uses thereof |
| EP19819402.9A EP3813946B1 (en) | 2018-06-15 | 2019-06-17 | Rapamycin analogs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240794T1 true HRP20240794T1 (hr) | 2024-09-13 |
Family
ID=68842366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240794TT HRP20240794T1 (hr) | 2018-06-15 | 2019-06-17 | Analozi rapamicina i njihove uporabe |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10980784B2 (hr) |
| EP (2) | EP3813946B1 (hr) |
| JP (2) | JP7382353B2 (hr) |
| KR (1) | KR20210021534A (hr) |
| CN (2) | CN117843659A (hr) |
| AU (1) | AU2019286524A1 (hr) |
| BR (1) | BR112020025283A2 (hr) |
| CA (1) | CA3103282A1 (hr) |
| CO (1) | CO2020015747A2 (hr) |
| DK (1) | DK3813946T3 (hr) |
| EA (1) | EA202092692A1 (hr) |
| ES (1) | ES2982253T3 (hr) |
| FI (1) | FI3813946T3 (hr) |
| HR (1) | HRP20240794T1 (hr) |
| IL (2) | IL314362A (hr) |
| LT (1) | LT3813946T (hr) |
| MX (2) | MX2020013630A (hr) |
| PL (1) | PL3813946T3 (hr) |
| PT (1) | PT3813946T (hr) |
| RS (1) | RS65761B1 (hr) |
| SG (1) | SG11202012447YA (hr) |
| SI (1) | SI3813946T1 (hr) |
| WO (1) | WO2019241789A1 (hr) |
| ZA (1) | ZA202309446B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3813946T3 (da) | 2018-06-15 | 2024-08-19 | Janssen Pharmaceutica Nv | Rapamycin-analoger og anvendelser deraf |
| EA202191983A1 (ru) | 2019-01-22 | 2021-12-01 | Аеовиан Фармасьютикалз, Инк. | МОДУЛЯТОРЫ mTORC И ИХ ПРИМЕНЕНИЕ |
| JP2023506410A (ja) | 2019-12-05 | 2023-02-16 | アナクリア セラピューティクス， インコーポレイテッド | ラパマイシン類似体及びその使用 |
| BR112022019508A2 (pt) | 2020-03-27 | 2022-11-16 | Aeovian Pharmaceuticals Inc | Moduladores de mtorc1 e seus usos |
| CN116322677A (zh) * | 2020-07-21 | 2023-06-23 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| BR112023014287A2 (pt) * | 2021-01-22 | 2023-11-21 | Janssen Pharmaceutica Nv | Análogos de rapamicina e usos dos mesmos |
| CN115097046B (zh) * | 2022-07-07 | 2023-09-26 | 国药集团川抗制药有限公司 | 一种分离雷帕霉素及其杂质的方法 |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| ZA935112B (en) * | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5260300A (en) | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
| AU6711994A (en) | 1993-04-23 | 1994-11-21 | American Home Products Corporation | Rapamycin conjugates and antibodies |
| CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| SG64372A1 (en) * | 1993-12-17 | 1999-04-27 | Novartis Ag | Rapamycin derivatives |
| US5362735A (en) * | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| JP3934705B2 (ja) | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | サイクロデキストリン組成物 |
| KR19990022651A (ko) | 1995-06-07 | 1999-03-25 | 데이비드 엘. 버스테인 | 생물학적 사건에 대한 라파마이신 기재 조절방법 |
| WO1996041807A1 (en) | 1995-06-09 | 1996-12-27 | Novartis Ag | Rapamycin derivatives |
| CA2257803C (en) | 1996-07-12 | 2008-12-02 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
| US5922730A (en) | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
| CN1235608A (zh) | 1996-09-09 | 1999-11-17 | 美国家用产品公司 | 烷基化的雷帕霉素衍生物 |
| US6342507B1 (en) | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| AU783158B2 (en) | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
| TWI256395B (en) | 1999-09-29 | 2006-06-11 | Wyeth Corp | Regioselective synthesis of rapamycin derivatives |
| EA006227B1 (ru) | 1999-12-10 | 2005-10-27 | Пфайзер Продактс Инк. | СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| DK1389617T3 (da) | 2001-04-27 | 2007-05-07 | Zenyaku Kogyo Kk | Heterocyclisk forbindelse og antitumormiddel indeholdende denne som den aktive bestanddel |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| CA2495072A1 (en) | 2002-08-14 | 2004-03-11 | Atugen Ag | Use of protein kinase n beta |
| JP2006523237A (ja) | 2003-04-03 | 2006-10-12 | セマフォア ファーマシューティカルズ， インコーポレイテッド | Ｐｉ−３キナーゼインヒビタープロドラッグ |
| KR101168441B1 (ko) | 2003-05-30 | 2012-07-25 | 게민 엑스 파마슈티컬스 캐나다 인코포레이티드 | 암 또는 바이러스 질환의 치료를 위한 삼복소환 화합물,조성물 및 방법 |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| US20060173033A1 (en) | 2003-07-08 | 2006-08-03 | Michaela Kneissel | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
| US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
| AU2005245875C1 (en) | 2004-05-13 | 2017-08-31 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| US20060189551A1 (en) * | 2004-10-04 | 2006-08-24 | Duke University | Combination therapies for fungal pathogens |
| EP2161275A1 (en) | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| US20060257337A1 (en) | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
| WO2007040650A2 (en) | 2005-05-12 | 2007-04-12 | Abbott Laboratories | Apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| ES2513165T3 (es) | 2005-10-07 | 2014-10-24 | Exelixis, Inc. | Derivados de N-(3-amino-quinoxalin-2-il)-sulfonamida y su uso como inhibidores de la fosfatidilinositol-3-quinasa |
| EA016945B1 (ru) | 2005-10-07 | 2012-08-30 | Экселиксис, Инк. | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα |
| BR122021011787B1 (pt) | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
| SI1951724T1 (sl) | 2005-11-17 | 2011-09-30 | Osi Pharmaceuticals Llc | Kondenzirani biciklični mTOR inhibitorji |
| UA116187C2 (uk) | 2005-12-13 | 2018-02-26 | Інсайт Холдінгс Корпорейшн | ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US20070203168A1 (en) | 2006-02-28 | 2007-08-30 | Zhao Jonathon Z | Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same |
| PE20080038A1 (es) | 2006-04-11 | 2008-02-22 | Smithkline Beecham Corp | Derivados de tiazolidinadiona como inhibidores de la pi3 quinasa |
| AR060631A1 (es) | 2006-04-26 | 2008-07-02 | Piramed Ltd | Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k) |
| US8197596B2 (en) | 2006-07-28 | 2012-06-12 | Pronomic Industry Ab | Crystal growth method and reactor design |
| EA016388B1 (ru) | 2006-09-15 | 2012-04-30 | Пфайзер Продактс Инк. | Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов |
| EP2532235A1 (en) | 2006-09-22 | 2012-12-12 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| JP5284977B2 (ja) | 2006-12-07 | 2013-09-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法 |
| WO2008110491A2 (en) | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
| KR20150043565A (ko) | 2007-03-12 | 2015-04-22 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| PT2288610T (pt) | 2008-03-11 | 2016-10-17 | Incyte Holdings Corp | Derivados de azetidina e de ciclobutano como inibidores de jak |
| US20090253733A1 (en) | 2008-04-02 | 2009-10-08 | Biointeractions, Ltd. | Rapamycin carbonate esters |
| ES2728163T3 (es) | 2008-05-23 | 2019-10-22 | Wyeth Llc | Compuestos de triazina como inhibidores de PI3 cinasa y mTOR |
| CN102137860B (zh) | 2008-06-20 | 2013-08-28 | 阿斯利康(瑞典)有限公司 | 吡啶并嘧啶化合物及其制备方法 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| ES2345241B1 (es) | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| SG174527A1 (en) | 2009-03-27 | 2011-11-28 | Pathway Therapeutics Inc | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| RU2506264C2 (ru) | 2009-04-03 | 2014-02-10 | Вэрастэм, Инк. | Пиримидин-замещенные пуриновые соединения в качестве ингибиторов киназы (или киназ) |
| US20100305093A1 (en) | 2009-04-09 | 2010-12-02 | Exelixis, Inc. | Inhibitors of mTOR and Methods of Making and Using |
| CA2800327A1 (en) | 2010-04-13 | 2011-10-20 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
| US9062046B2 (en) | 2010-07-16 | 2015-06-23 | Piramal Enterprises Limited | Substituted imidazoquinoline derivatives as kinase inhibitors |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| EP2589383A1 (en) | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
| US8808256B2 (en) | 2012-01-16 | 2014-08-19 | Johnson & Johnson Vision Care, Inc. | Eye drug delivery system |
| US9072678B2 (en) | 2013-03-14 | 2015-07-07 | Pathak Holdings Llc | Methods for local drug delivery by microinjection |
| WO2015051043A1 (en) | 2013-10-01 | 2015-04-09 | Amgen Inc. | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors |
| RS59007B1 (sr) | 2014-02-03 | 2019-08-30 | Vitae Pharmaceuticals Llc | Dihidropirolopiridinski inhibitori ror-gama |
| CN107073066B (zh) | 2014-09-11 | 2021-09-17 | 加利福尼亚大学董事会 | mTORC1抑制剂 |
| US20160279108A1 (en) | 2015-02-24 | 2016-09-29 | University Of Kansas | Targeted mtor inhibitors |
| WO2017044720A1 (en) | 2015-09-11 | 2017-03-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| KR20200012876A (ko) | 2017-05-02 | 2020-02-05 | 레볼루션 메디슨즈, 인크. | mTOR 억제제로서의 파라마이신 유사체 |
| UY37900A (es) | 2017-09-26 | 2019-04-30 | Novartis Ag | Nuevos derivados de rapamicina |
| DK3813946T3 (da) | 2018-06-15 | 2024-08-19 | Janssen Pharmaceutica Nv | Rapamycin-analoger og anvendelser deraf |
| WO2020076738A2 (en) | 2018-10-12 | 2020-04-16 | Bellicum Pharmaceuticals, Inc | Protein-binding compounds |
| CN113260619A (zh) | 2018-12-18 | 2021-08-13 | 诺华股份有限公司 | 雷帕霉素衍生物 |
| EA202191983A1 (ru) | 2019-01-22 | 2021-12-01 | Аеовиан Фармасьютикалз, Инк. | МОДУЛЯТОРЫ mTORC И ИХ ПРИМЕНЕНИЕ |
| LT3947392T (lt) | 2019-03-26 | 2024-05-27 | Novartis Ag | Izotiazolidino 1,1-dioksidas ir 1,4-butano sultonas, kurių sudėtyje yra rapamicino dariniai ir jų panaudojimas |
| BR112022019508A2 (pt) | 2020-03-27 | 2022-11-16 | Aeovian Pharmaceuticals Inc | Moduladores de mtorc1 e seus usos |
| CN116322677A (zh) | 2020-07-21 | 2023-06-23 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
-
2019
- 2019-06-17 DK DK19819402.9T patent/DK3813946T3/da active
- 2019-06-17 MX MX2020013630A patent/MX2020013630A/es unknown
- 2019-06-17 FI FIEP19819402.9T patent/FI3813946T3/fi active
- 2019-06-17 CN CN202311390677.6A patent/CN117843659A/zh active Pending
- 2019-06-17 LT LTEPPCT/US2019/037507T patent/LT3813946T/lt unknown
- 2019-06-17 ES ES19819402T patent/ES2982253T3/es active Active
- 2019-06-17 CN CN201980047384.3A patent/CN112423843B/zh active Active
- 2019-06-17 EA EA202092692A patent/EA202092692A1/ru unknown
- 2019-06-17 PL PL19819402.9T patent/PL3813946T3/pl unknown
- 2019-06-17 SG SG11202012447YA patent/SG11202012447YA/en unknown
- 2019-06-17 SI SI201930762T patent/SI3813946T1/sl unknown
- 2019-06-17 RS RS20240760A patent/RS65761B1/sr unknown
- 2019-06-17 HR HRP20240794TT patent/HRP20240794T1/hr unknown
- 2019-06-17 IL IL314362A patent/IL314362A/en unknown
- 2019-06-17 IL IL279329A patent/IL279329B1/en unknown
- 2019-06-17 EP EP19819402.9A patent/EP3813946B1/en active Active
- 2019-06-17 JP JP2020569883A patent/JP7382353B2/ja active Active
- 2019-06-17 AU AU2019286524A patent/AU2019286524A1/en active Pending
- 2019-06-17 BR BR112020025283-2A patent/BR112020025283A2/pt unknown
- 2019-06-17 PT PT198194029T patent/PT3813946T/pt unknown
- 2019-06-17 EP EP23209520.8A patent/EP4302827A3/en active Pending
- 2019-06-17 KR KR1020217001301A patent/KR20210021534A/ko not_active Application Discontinuation
- 2019-06-17 CA CA3103282A patent/CA3103282A1/en active Pending
- 2019-06-17 US US16/443,298 patent/US10980784B2/en active Active
- 2019-06-17 WO PCT/US2019/037507 patent/WO2019241789A1/en active Application Filing
-
2020
- 2020-11-25 US US17/104,771 patent/US11944605B2/en active Active
- 2020-12-14 MX MX2024008964A patent/MX2024008964A/es unknown
- 2020-12-15 CO CONC2020/0015747A patent/CO2020015747A2/es unknown
-
2023
- 2023-10-10 ZA ZA2023/09446A patent/ZA202309446B/en unknown
- 2023-11-06 JP JP2023189414A patent/JP2024012524A/ja active Pending
- 2023-12-04 US US18/528,215 patent/US20240173305A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240794T1 (hr) | Analozi rapamicina i njihove uporabe | |
| JP2020505381A5 (hr) | ||
| HRP20171829T1 (hr) | 2-piridil supstituirani imidazoli kao terapijski inhibitori alk5 i/ili alk4 | |
| JP2018513188A5 (hr) | ||
| HRP20100559T1 (hr) | Liječenje neovaskularnih poremećaja oka, poput makularne degeneracije, angioidnih strija, uveitisa i edema makule | |
| JP2018535963A5 (hr) | ||
| JP2018513107A5 (hr) | ||
| JP2017526716A5 (hr) | ||
| JP2017105802A5 (hr) | ||
| JP2013500977A5 (hr) | ||
| JP2019520361A5 (hr) | ||
| HRP20240697T1 (hr) | Derivati n-metil, n-(6-(metoksi)piridazin-3-il) amina kao modulatori autotaksina (atx) za liječenje upalnih bolesti dišnih puteva ili fibroznih bolesti | |
| JP2017532294A5 (hr) | ||
| Almeida et al. | Effect of peritoneal dialysis vs. haemodialysis on respiratory mechanics in acute kidney injury patients | |
| Roman-Filip et al. | Therapeutic plasma exchange and double filtration plasmapheresis in severe neuroimmune disorders | |
| HRP20240831T1 (hr) | Derivati 1-(6-(metoksi)piridazin-3-il)ciklopropan-1-karboksamida kao modulatori autotaksina (atx) za liječenje upalnih bolesti dišnih puteva | |
| CN115605194A (zh) | 过度炎症综合征的治疗 | |
| JP2014517078A5 (hr) | ||
| JP2006524699A5 (hr) | ||
| HRP20231469T1 (hr) | Poboljšani protokol za liječenje lupus nefritisa | |
| US20100227917A1 (en) | EYE DROP CONTAINING DIBENZ[b,e]OXEPIN DERIVATIVE | |
| RU2017111579A (ru) | Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина | |
| WO2008076296A3 (en) | D-ribose for treating suboptimal pulmonary function | |
| Wong et al. | Albuterol for the treatment of hyperkalemia | |
| Hasegawa et al. | A case of continuous venovenous hemofiltration for anuric acute kidney injury with severe hyponatremia: A simple method involving flexible adjustment of sodium replacement solution |